<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005476.pub4" GROUP_ID="GYNAECA" ID="870404112416321143" MERGED_FROM="" MODIFIED="2015-04-20 12:42:15 +0100" MODIFIED_BY="Clare Jess" REVIEW_NO="H016" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2015-04-20 12:42:15 +0100" MODIFIED_BY="Clare Jess">
<TITLE MODIFIED="2011-03-04 13:11:20 +0000" MODIFIED_BY="[Empty name]">Laetrile treatment for cancer</TITLE>
<CONTACT MODIFIED="2015-04-20 12:42:15 +0100" MODIFIED_BY="Clare Jess"><PERSON ID="FBC0939382E26AA201D44AE91D9448F5" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Stefania</FIRST_NAME><LAST_NAME>Milazzo</LAST_NAME><POSITION>Research Fellow</POSITION><EMAIL_1>stesincro@yahoo.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Internal Medicine, Division of Oncology and Hematology</DEPARTMENT><ORGANISATION>Paracelsus Medical University, Klinikum Nuernberg</ORGANISATION><ADDRESS_1>Prof.-Ernst-Nathan-Str. 1</ADDRESS_1><CITY>Nuernberg</CITY><ZIP>D-90419</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49 911 398 3056</PHONE_1><FAX_1>+49 911 398 2724</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2015-04-20 12:42:15 +0100" MODIFIED_BY="Clare Jess"><PERSON ID="FBC0939382E26AA201D44AE91D9448F5" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Stefania</FIRST_NAME><LAST_NAME>Milazzo</LAST_NAME><POSITION>Research Fellow</POSITION><EMAIL_1>stesincro@yahoo.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Internal Medicine, Division of Oncology and Hematology</DEPARTMENT><ORGANISATION>Paracelsus Medical University, Klinikum Nuernberg</ORGANISATION><ADDRESS_1>Prof.-Ernst-Nathan-Str. 1</ADDRESS_1><CITY>Nuernberg</CITY><ZIP>D-90419</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49 911 398 3056</PHONE_1><FAX_1>+49 911 398 2724</FAX_1></ADDRESS></PERSON><PERSON ID="13696" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Markus</FIRST_NAME><LAST_NAME>Horneber</LAST_NAME><POSITION>Consultant</POSITION><EMAIL_1>horneber@klinikum-nuernberg.de</EMAIL_1><URL>www.med5-nbg.de</URL><ADDRESS><DEPARTMENT>Department of Internal Medicine, Division of Oncology and Hematology</DEPARTMENT><ORGANISATION>Paracelsus Medical University, Klinikum Nuernberg</ORGANISATION><ADDRESS_1>Prof.-Ernst-Nathan-Str. 1</ADDRESS_1><CITY>Nuernberg</CITY><ZIP>D-90419</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49 911 398 3056</PHONE_1><FAX_1>+49 911 398 2724</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2015-04-20 12:12:49 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="31" MONTH="10" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="31" MONTH="10" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="30" MONTH="4" YEAR="2018"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2006"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2015-04-20 09:33:01 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-04-20 09:32:42 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="20" MONTH="4" YEAR="2015"/>
<DESCRIPTION>
<P>Literature searches updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-04-20 09:33:01 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="20" MONTH="4" YEAR="2015"/>
<DESCRIPTION>
<P>No studies identified for inclusion.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-04-20 09:31:38 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-04-20 09:31:38 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="3" MONTH="8" YEAR="2011"/>
<DESCRIPTION>
<P>New author added and contact details revised.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-04-20 09:31:32 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="17" MONTH="6" YEAR="2011"/>
<DESCRIPTION>
<P>Update of the literature search and complete revision of the text. No studies identified for inclusion.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-10-23 14:49:11 +0100" MODIFIED_BY="Gail Quinn">
<DATE DAY="16" MONTH="2" YEAR="2006"/>
<DESCRIPTION>
<P>Minor update: 16/02/06</P>
<P>Feedback added: 15/08/06</P>
<P>Response to feedback added: 04/01/07</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="6" MONTH="1" YEAR="2006"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2015-04-16 11:31:21 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2015-04-16 11:31:21 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2011-07-05 19:42:32 +0100" MODIFIED_BY="[Empty name]">
<NAME>FP5 project &#8220;Concerted Action for Complementary and Alternative Medicine Assessment in the Cancer Field (CAM-Cancer)&#8221;, Quality of life and manage­ment of living resources programme, European Commission [QLRT- 2001- 00786]</NAME>
<COUNTRY CODE="NONE">Other</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2011-06-16 19:46:57 +0100" MODIFIED_BY="[Empty name]">
<NAME>Cochrane Gynecologic Cancer Group, Bath</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2011-07-05 19:43:04 +0100" MODIFIED_BY="[Empty name]">
<NAME>AG Biologische Krebstherapie, Deutsche Krebshilfe (70-301)</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION>
<P>All funding sources had no role in designing, conducting or writing this systematic review. The contents of this systematic review are solely the responsibility of the authors and do not necessarily represent the official views of the funding institutions.</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2015-04-16 11:31:21 +0100" MODIFIED_BY="[Empty name]">
<NAME>Kompetenznetz Komplementärmedizin in der Onkologie - KOKON</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION>
<P>Förderungsschwerpunkt der Deutschen Krebshilfe e.V. (Projekt-Nr. 109863)</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-04-20 12:27:54 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2015-04-20 12:15:26 +0100" MODIFIED_BY="[Empty name]">
<TITLE>Laetrile treatment for cancer</TITLE>
<SUMMARY_BODY MODIFIED="2015-04-20 12:15:26 +0100" MODIFIED_BY="[Empty name]">
<P>Laetrile is a word created from the first letters of laevorotatory and mandelonitrile and describes a semi-synthetic form of amygdalin. Amygdalin is a compound that can be isolated from the seeds of many fruits such as peaches, bitter almonds and apricots. Both laetrile and amygdalin have a common structural component, mandelonitrile, that contains cyanide.</P>
<P>The lack of laetrile's effectiveness and the risk of side effects from cyanide poisoning led the Food and Drugs Agency (FDA) in the US and the European Commission to ban its use. However, it is possible to buy laetrile or amygdalin via the Internet. As there is no government control of these markets, preparations may not only come from questionable sources but they may also be contaminated. Cancer patients should be informed about the high risk of developing serious adverse effects due to cyanide poisoning after laetrile or amygdalin, especially after oral ingestion. This risk could increase with concomitant intake of vitamin C and in vegetarians with vitamin B12 deficiency.</P>
<P>This systematic review found that there is no reliable evidence for the alleged effects of laetrile or amygdalin for curative effects in cancer patients.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-04-20 12:27:54 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2011-09-01 10:29:29 +0100" MODIFIED_BY="Clare Jess">
<P>Laetrile is the name for a semi-synthetic compound which is chemically related to amygdalin, a cyanogenic glycoside from the kernels of apricots and various other species of the genus <I>Prunus</I>. Laetrile and amygdalin are promoted under various names for the treatment of cancer although there is no evidence for its efficacy. Due to possible cyanide poisoning, laetrile can be dangerous.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2011-08-03 10:50:46 +0100" MODIFIED_BY="Clare Jess">
<P>To assess the alleged anti-cancer effect and possible adverse effects of laetrile and amygdalin.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-04-20 12:14:48 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the following databases: CENTRAL (2014, Issue 9); MEDLINE (1951-2014); EMBASE (1980-2014); AMED; Scirus; CINAHL (all from 1982-2015); CAMbase (from 1998-2015); the MetaRegister; the National Research Register; and our own files. We examined reference lists of included studies and review articles and we contacted experts in the field for knowledge of additional studies. We did not impose any restrictions of timer or language.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2011-09-01 10:29:55 +0100" MODIFIED_BY="Clare Jess">
<P>Randomized controlled trials (RCTs) and quasi-RCTs.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2011-09-01 10:30:01 +0100" MODIFIED_BY="Clare Jess">
<P>We searched eight databases and two registers for studies testing laetrile or amygdalin for the treatment of cancer. Two review authors screened and assessed articles for inclusion criteria.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-04-20 12:27:54 +0100" MODIFIED_BY="[Empty name]">
<P>We located over 200 references, 63 were evaluated in the original review, 6 in the 2011 and none in this update. However, we did not identify any studies that met our inclusion criteria.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2011-08-04 13:04:04 +0100" MODIFIED_BY="[Empty name]">
<P>The claims that laetrile or amygdalin have beneficial effects for cancer patients are not currently supported by sound clinical data. There is a considerable risk of serious adverse effects from cyanide poisoning after laetrile or amygdalin, especially after oral ingestion. The risk&#8211;benefit balance of laetrile or amygdalin as a treatment for cancer is therefore unambiguously negative.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-04-20 12:25:37 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2015-04-16 11:51:30 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2011-07-01 18:20:54 +0100" MODIFIED_BY="[Empty name]">
<P>Many surveys have reported that many people suffering from cancer turn towards so-called alternative cancer cures, hoping for an effective therapy. However, few alternative cancer therapies are backed up by encouraging evidence. Some of them are associated with high-risks (<LINK REF="REF-Gibbs-2004" TYPE="REFERENCE">Gibbs 2004</LINK>), and the quality of information about complementary and alternative medicine (CAM) for cancer treatment has the potential to seriously mislead patients (<LINK REF="REF-Schmidt-2004" TYPE="REFERENCE">Schmidt 2004</LINK>). Many websites suggest a variety of alternative cancer cures and most of them advertise and sell such products illegally (<LINK REF="REF-Barrett-2011" TYPE="REFERENCE">Barrett 2011</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2011-09-01 10:30:28 +0100" MODIFIED_BY="Clare Jess">
<SUBSECTION>
<HEADING LEVEL="2">Amygdalin</HEADING>
<P>Amygdalin is a cyanogenic glycoside plant compound found in the kernels of many fruits and in numerous plants belonging to the genus of <I>Prunus</I> (<LINK REF="REF-Vetter-2000" TYPE="REFERENCE">Vetter 2000</LINK>) Amygdalin consists of a gentiobiose, a disaccharide composed of two units of D-glucose, and mandelonitrile (<LINK REF="REF-Kwon-2003" TYPE="REFERENCE">Kwon 2003</LINK>). Amygdalin was first isolated in 1830 by two French chemists Robiquet and Boutron-Charlard (<LINK REF="REF-Dorr-1978" TYPE="REFERENCE">Dorr 1978</LINK>). Orally administered amygdalin is thought to be hydrolyzed into prunasin and glucose by human digestive enzymes and prunasin is further degraded into mandelonitrile in the small intestine. Transformation of mandelonitrile into benzaldehyde and cyanide and the subsequent toxicity is mainly due to gut microflora (<LINK REF="REF-Shim-2010" TYPE="REFERENCE">Shim 2010</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Laetrile</HEADING>
<P>In the 1950s, an intravenous form of amygdalin was patented and named laetrile, which is an acronym from <B>lae</B>vorotatory and mandeloni<B>trile</B>. The form that was patented in the USA, albeit not approved, is a semisynthetic compound consisting of D-glucoronic acid and mandelonitrile, while laetrile made in Mexico is extracted from crushed apricot kernels consists of amygdalin. (<LINK REF="REF-Dorr-1978" TYPE="REFERENCE">Dorr 1978</LINK>; <LINK REF="REF-Fenselau-1977" TYPE="REFERENCE">Fenselau 1977</LINK>).</P>
<P>Laetrile is prepared for oral as well as for intravenous or intramuscular application. The results of an analysis conducted by the National Cancer Institute (NCI) in order to assess the purity of both oral and injectable amygdalin products indicated that they were substandard by US criteria for pharmaceutical products (<LINK REF="REF-Davignon-1978" TYPE="REFERENCE">Davignon 1978</LINK>). Other studies also showed the presence of contaminants in both injectable and oral supplements of laetrile (<LINK REF="REF-Dorr-1978" TYPE="REFERENCE">Dorr 1978</LINK>). Shaffer reported that the FDA deemed that laetrile products were toxic and ineffective and laetrile was consequently banned from US-interstate transportation (<LINK REF="REF-Shaffer-1979" TYPE="REFERENCE">Shaffer 1979</LINK>). However, in 1980 the Associated Press reported that 23 US States had legalized the use of the laetrile within their boundaries and for the treatment of terminal cancer patients (<LINK REF="REF-Curran-1980" TYPE="REFERENCE">Curran 1980</LINK>). During the 1970s at least 70,000 Americans had used laetrile (<LINK REF="REF-Ellison-1978" TYPE="REFERENCE">Ellison 1978</LINK>).</P>
<P>Laetrile's proponents consider it to be a "natural cancer cure"; whereas opponents consider "the slickest, most sophisticated, and certainly the most remunerative cancer quack promotion in medical history" (<LINK REF="REF-Lerner-1981" TYPE="REFERENCE">Lerner 1981</LINK>).</P>
</SUBSECTION>
</INTERVENTION>
<THEORY MODIFIED="2011-09-01 10:30:35 +0100" MODIFIED_BY="Clare Jess">
<P>Cyanide released from enzymatic degradation of laetrile or amygdalin is believed to be the ingredient responsible for the alleged anti-cancer action. Proponents claim that malignant cells are specifically vulnerable to cyanogenic glycosides because of two characteristics: a higher level of beta-glucosidases and beta-glucuronidase compared to normal cells, which would lead to a more rapid intracellular release of cyanide from laetrile or amygdalin and a deficiency in rhodanese, an enzyme that converts cyanide into the harmless compound thiocyanate. Another theory claims that cancer develops due to the deficiency of a vitamin, named "vitamin B17", which was the name that the chemist E.T. Krebs gave to laetrile (theories reviewed in <LINK REF="REF-NCI-2011" TYPE="REFERENCE">NCI 2011</LINK>).</P>
<P>Recent in-vitro studies suggested possible anti-cancer effects of amygdalin (<LINK REF="REF-Chang-2006" TYPE="REFERENCE">Chang 2006</LINK>; <LINK REF="REF-Fukuda-2003" TYPE="REFERENCE">Fukuda 2003</LINK>; <LINK REF="REF-Kwon-2003" TYPE="REFERENCE">Kwon 2003</LINK>; <LINK REF="REF-Park-HJ-2005" TYPE="REFERENCE">Park HJ 2005</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2015-04-16 11:51:30 +0100" MODIFIED_BY="[Empty name]">
<P>After a best case series in 1978, the NCI conducted a phase I and phase II trial. Their results suggested that oral ingestion of laetrile or amygdalin raises the risk of cyanide poisoning and that the number of patients who showed a tumor response after the application of amygdalin was minimal: one out of 175 evaluable patients met the criteria for a tumor response (<LINK REF="STD-Moertel-1982" TYPE="STUDY">Moertel 1982</LINK>).</P>
<P>Laetrile has been banned by the FDA since the 1980s and it is not authorized for sale as a medicinal product in the European Community (<LINK REF="REF-Meijer-2001" TYPE="REFERENCE">Meijer 2001</LINK>). Nevertheless, it continues to be manufactured and administered as an anti-cancer therapy (<LINK REF="REF-Lilienthal-2014" TYPE="REFERENCE">Lilienthal 2014</LINK>). Over the last years websites have again started promoting and selling laetrile, amygdalin and apricot pits (<LINK REF="REF-Barrett-2011" TYPE="REFERENCE">Barrett 2011</LINK>) and questionable claims are made concerning benefits for cancer patients (reviewed in <LINK REF="REF-Lilienthal-2014" TYPE="REFERENCE">Lilienthal 2014</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2011-08-04 12:18:25 +0100" MODIFIED_BY="[Empty name]">
<P>To determine the effectiveness and tolerability of laetrile and or amygdalin for the treatment of cancer patients.</P>
</OBJECTIVES>
<METHODS MODIFIED="2015-04-20 12:24:32 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2011-09-01 10:30:48 +0100" MODIFIED_BY="Clare Jess">
<CRIT_STUDIES MODIFIED="2011-09-01 10:30:44 +0100" MODIFIED_BY="Clare Jess">
<P>Randomized controlled trials (RCTs), including cluster and cross-over trials and quasi-RCTs (assigning patients to groups based on date, order of entry, birth date etc.).</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2011-07-01 19:17:43 +0100" MODIFIED_BY="[Empty name]">
<P>Any adult patients with histologically proven malignant diseases of any stage.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2011-09-01 10:30:47 +0100" MODIFIED_BY="Clare Jess">
<SUBSECTION>
<HEADING LEVEL="4">Intervention</HEADING>
<P>Oral or parenteral (intravenous or intramuscular) preparations of laetrile, amygdalin, or from the seed of <I>Prunus</I> species.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Control Interventions</HEADING>
<P>Control groups could consist of placebo, conventional standard treatment, or no treatment, or waiting lists.</P>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2011-09-01 10:30:48 +0100" MODIFIED_BY="Clare Jess">
<P>The outcomes of interest were:<BR/>
</P>
<UL>
<LI>Overall survival (OS),</LI>
<LI>Disease-free survival (DFS) and progression-free survival (PFS),</LI>
<LI>Tumor response (parameters for response had to be defined or follow standard criteria (WHO (<LINK REF="REF-Miller-1981" TYPE="REFERENCE">Miller 1981</LINK>), RECIST (<LINK REF="REF-Therasse-2000" TYPE="REFERENCE">Therasse 2000</LINK>)),</LI>
<LI>Adverse events related to the intervention.</LI>
</UL>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-04-20 12:24:32 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2015-04-20 12:24:32 +0100" MODIFIED_BY="[Empty name]">
<P>For the previous version of the review we searched the following databases for the indicated time periods or from inception of the database: The Cochrane Central Register of Controlled Trials (CENTRAL, 2011, Issue 1); MEDLINE (1951-2011); EMBASE (1980-2011); AMED; Scirus; CancerLit; CINAHL (all from 1982-2011); CAMbase (from 1998-2011). For this update we searched The Cochrane Central Register of Controlled Trials (CENTRAL, 2014, Issue 9); MEDLINE (Oct week 3, 2014); EMBASE (2014, week 43); AMED; Scirus; CINAHL (all from 2011-2015); CAMbase (2011-2015). See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for list of electronic search strategies.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2015-04-20 10:37:29 +0100" MODIFIED_BY="[Empty name]">
<P>For ongoing trials, we searched the following databases: Clinical Trials of the American Cancer Society (<A HREF="http://www.cancer.gov">http://www.cancer.gov</A>, April 2015), the metaRegister of Controlled Trials (mRCT, <A HREF="http://www.controlled-trials.com">http://www.controlled-trials.com</A>, April 2015) and the German Cancer Study Register (<A HREF="http://www.studien.de">http://www.studien.de</A>, April 2015). In addition, we scanned the bibliographies of all located studies to identify unpublished or on-going trials through correspondence with experts in the field. Finally, we handsearched our own files for further studies.<BR/>
</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-04-20 10:10:53 +0100" MODIFIED_BY="[Empty name]">
<P>We downloaded all titles and abstracts retrieved by the searches to a reference management database.We removed duplicates and two review authors independently examined the remaining references (SM, MH). We obtained the full texts for potentially relevant studies and reviewed them for inclusion based on predetermined criteria. We resolved disagreement by discussion.<BR/>
</P>
<SUBSECTION>
<HEADING LEVEL="3">Methods for future updates</HEADING>
<P>The updated search of this review again did not retrieve any studies which met the inclusion criteria. If eligible trials are identified in further updates, we will apply the review methods reproduced in <LINK TAG="PRO_REV_DIFF" TYPE="SECTION">Differences between protocol and review</LINK>.</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-04-20 12:25:37 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2015-04-20 12:25:37 +0100" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2015-04-20 12:25:37 +0100" MODIFIED_BY="[Empty name]">
<P>The searches up to Feb 2011 identified 69 potentially relevant references (63 for the original review and 6 for this update). After screening the titles and abstracts, we obtained full publications of 40 references for detailed evaluation. We excluded all 40 for the following reasons: not randomized (1 study), case reports (25 studies), best case series (6 studies), consecutive case series (3 studies), non-consecutive case series (2 studies), benzaldehyde treatment rather than laetrile or amygdalin (2 studies), patients with benign tumors (1 study) (<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>). Searches of trial registries did not identify any ongoing and eligible trials in this area. CENTRAL, MEDLINE and EMBASE searches up to October 2014 and CINAHL, CAMbase and author team topic knowledge up to April 2015 did not identify any studies for inclusion.</P>
</SEARCH_RESULTS>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2011-07-01 19:18:33 +0100" MODIFIED_BY="[Empty name]">
<P>No study met the inclusion criteria.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2011-07-01 19:18:37 +0100" MODIFIED_BY="[Empty name]">
<P>No study met the inclusion criteria.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2011-09-01 10:31:31 +0100" MODIFIED_BY="Clare Jess">
<SUMMARY_OF_RESULTS MODIFIED="2011-08-04 12:18:53 +0100" MODIFIED_BY="[Empty name]">
<P>There were no RCTs or quasi-RCTs investigating the effectiveness of laetrile or amygdalin for the treatment of cancer. Despite the utilization of laetrile and amygdalin, this systematic review found no evidence for laetrile or amygdalin to be effective as anti-cancer agents.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2011-08-31 17:44:43 +0100" MODIFIED_BY="Heather Maxwell">
<P>Not applicable.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2011-08-31 17:44:44 +0100" MODIFIED_BY="Heather Maxwell">
<P>Not applicable.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2011-09-01 10:31:29 +0100" MODIFIED_BY="Clare Jess">
<P>Strengths of this review include the use of extensive search terms and multiple databases to ensure a comprehensive search. Limitations include the possibility that we overlooked trials with other cyanogenic glycosides, given their large number in the plant kingdom.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2011-09-01 10:31:31 +0100" MODIFIED_BY="Clare Jess">
<P>As this systematic review found no evidence from RCTs or quasi-RCTs for the use of laetrile or amygdalin in cancer treatment, nothing must be added to the conclusion of an editorial that was written after the publication of a clinical trial of amygdalin for the treatment of advanced cancer from the NCI: "(...) The evidence, beyond reasonable doubt, is that it [laetrile] doesn't benefit patients with advanced cancer, and there is no reason to believe that it would be any more effective in the earlier stages of the disease." (<LINK REF="REF-Relman-1982" TYPE="REFERENCE">Relman 1982</LINK>)</P>
<P>Our search strategy was aimed at identifying clinical trials. This approach generates little information about risks. Yet the high risk of developing serious adverse effects from cyanide poisoning after laetrile or amygdalin, especially after oral ingestion, is considerable. This risk could increase with a concomitant intake of vitamin C (<LINK REF="REF-Bromley-2005" TYPE="REFERENCE">Bromley 2005</LINK>), in people with a genetic predisposition to a diminished capacity to detoxify cyanide (<LINK REF="REF-Calabrese-1979b" TYPE="REFERENCE">Calabrese 1979b</LINK>) and in vegetarians with vitamin B12 deficiency (<LINK REF="REF-Chan-2006" TYPE="REFERENCE">Chan 2006</LINK>). Practitioners and patients should also be aware that cyanide poisoning could be related to overdosing and to the quality of the products available on the market. Processing conditions are the main factors affecting the quality of some <I>Rosaceae </I>seeds (<LINK REF="REF-Hu-2002" TYPE="REFERENCE">Hu 2002</LINK>; <LINK REF="REF-Hwang-2002" TYPE="REFERENCE">Hwang 2002</LINK>), and often laetrile and amygdalin preparations come from questionable sources with no standards of quality or purity. These preparations might be mutagenic (<LINK REF="REF-Fenselau-1977" TYPE="REFERENCE">Fenselau 1977</LINK>) or could contain bacteria (<LINK REF="REF-Davignon-1978" TYPE="REFERENCE">Davignon 1978</LINK>) and other contaminants and impurities (<LINK REF="REF-Dorr-1978" TYPE="REFERENCE">Dorr 1978</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2011-09-01 10:31:34 +0100" MODIFIED_BY="Clare Jess">
<IMPLICATIONS_PRACTICE MODIFIED="2011-09-01 10:31:34 +0100" MODIFIED_BY="Clare Jess">
<P>There is no evidence from RCTs or quasi-RCTs that support the use of laetrile or preparations containing amygdalin in cancer patients. Due to the risk of cyanide poisoning, the use of laetrile or amygdalin should be discouraged.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2011-08-04 12:19:06 +0100" MODIFIED_BY="[Empty name]">
<P>On the basis of the available data, there is neither scientific nor ethical justification for clinical trials with laetrile or amygdalin in the management of cancer at the moment.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-04-20 12:11:24 +0100" MODIFIED_BY="[Empty name]">
<P>We would like to thank all members of the Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group and Heather Dickinson for their valuable support. We would also like to thank Leala Watson from the Complementary Medicine Peninsula Medical School, Exeter, for the valuable support with the literature search of this review update in 2011.</P>
<P>We would like to thank Edzard Ernst, Stephane Lejeune and Katja Boehm for their contribution to the original review in 2008.</P>
<P>This project was supported by the National Institute for Health Research, via Cochrane Infrastructure, Cochrane Programme Grant or Cochrane Incentive funding to the Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>We certify that we have no affiliations with or involvement in any organization or entity with a direct financial interest in the subject matter of the review.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-04-20 12:09:58 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="2">First version of the review</HEADING>
<P>Draft protocol (SM with contributions from all). Ran searches (SM). Identified relevant titles (SM, SL, KB, EE). Selected eligible trials (SM, SL, KB, EE). Drafted final review (SM with contribution from all).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Updated version of the review 2011</HEADING>
<P>Update of the literature search and revision of the text (SM, MH). Comments on the updated text (EE, SL).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Updated version of the review 2011</HEADING>
<P>Update of the literature search and revision of the text (SM, MH).</P>
</SUBSECTION>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2015-04-20 09:58:38 +0100" MODIFIED_BY="[Empty name]">
<P>If in any future update studies are identified for inclusion we will use the following methodology:</P>
<P>
<B>Data extraction and management</B>
</P>
<P>Data will be independently extracted unblinded to the study authors by at least two review authors using a predefined extraction form. All disagreements will be resolved by discussion.</P>
<P>We will extract the following information : author, year of publication, country and language of publication, funding source, objectives, study design, characteristics of participants including age, gender, number of participants who were eligible, enrolled and completed the study, diagnostic criteria and procedures, presence of intention-to-treat or per protocol analysis, method of sequence generation and randomization, blinding and allocation concealment, numbers and reasons for withdrawals and dropouts, details on intervention (type of preparation, dosage, chemical structure) and control treatment, duration of follow-up, time to event data (we will extract the median or mean survival times and their spread or confidence interval (CI)), dichotomous outcomes (e.g. adverse events, deaths, disease recurrence, disease progression, tumor response; we will extract the number of patients in each treatment arm who experienced the outcome of interest and the number of patients assessed at the endpoint in order to estimate a risk ratio (RR), adverse events (type and incidence of events and grades of toxicity).</P>
<P>If necessary, we will contact principal authors for further details of each study.</P>
<P>
<B>Assessment of risk of bias in included studies</B>
</P>
<P>Two review authors will independently assess methodological quality, using The Cochrane Collaboration 'Risk of bias' tool. We will resolve disagreement by discussion.</P>
<P>
<B>Measures of treatment effect</B>
</P>
<P>For time to event data, we will extract the hazard ratio (HR) and its variance from trial reports. If these are not presented, we will extract the data required to estimate them using Parmar's methods (<LINK REF="REF-Parmar-1998" TYPE="REFERENCE">Parmar 1998</LINK>), e.g. number of events in each arm and log-rank P value comparing the relevant outcomes in each arm. If it is not possible to estimate the HR, we will extract the number of patients in each treatment arm who experienced the outcome of interest, in order to estimate a RR.</P>
<P>We will present dichotomous data as RR with corresponding CIs. We will also determine the number needed to treat (for improvement) (NNTB) and the number needed to harm (NNTH) (for adverse events) for statistically significant outcomes.</P>
<P>We will present continuous data as mean differences (MD) for common measurement units or standardized mean differences (SMD) for differing measurement units and different scales, along with corresponding CIs.</P>
<P>
<B>Unit of analysis issues</B>
</P>
<P>For studies with comparable treatment groups, we will enter data for studies with more than one active treatment arm separately into the meta-analysis and we will evenly divide the control arm data as much as possible between entries.</P>
<P>
<B>Dealing with missing data</B>
</P>
<P>In instances where information is missing, we will contact study authors to provide the information.</P>
<P>
<B>Assessment of heterogeneity</B>
</P>
<P>We will quantify heterogeneity with the I<SUP>2</SUP> statistic (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>).</P>
<P>
<B>Assessment of reporting bias</B>
</P>
<P>We will assess publication bias visually using funnel plots (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>).</P>
<P>
<B>Data synthesis</B>
</P>
<P>We will use random-effects models for the primary analyses.</P>
<P>
<B>Subgroup analysis and investigation of heterogeneity</B>
</P>
<P>We will assess heterogeneity between studies by visual inspection of forest plots, by estimation of the percentage heterogeneity between trials which cannot be ascribed to sampling variation (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>) and by a formal statistical test of the significance of the heterogeneity (<LINK REF="REF-Egger-2001" TYPE="REFERENCE">Egger 2001</LINK>).</P>
<P>
<B>Sensitivity analysis</B>
</P>
<P>We will apply subgroup analyses omitting studies with a high risk of bias.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-04-20 10:06:16 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2011-09-01 11:00:44 +0100" MODIFIED_BY="Clare Jess">
<INCLUDED_STUDIES/>
<EXCLUDED_STUDIES MODIFIED="2011-09-01 11:00:44 +0100" MODIFIED_BY="Clare Jess">
<STUDY DATA_SOURCE="PUB" ID="STD-Ames-1981" NAME="Ames 1981" YEAR="1981">
<REFERENCE NOTES="&lt;p&gt;Since neither randomised controlled clinical trials (RCTs) nor controlled clinical trials (CCTs) have been carried out so far, no data extraction could be carried out in our systematic review and our main questions remained not answered. &lt;/p&gt;&lt;p&gt;In most of the studies dealing with Laetrile, generally no details regarding chemical structure, brand name, extraction process, purification methods are given; and often this term is used interchangeably with amygdalin or even Vitamin B17, which is not been demonstrated to be a vitamin. Other names are used to report Laetrile interventions were: D-mandelonitrile-&amp;#223;-D-glucosido-6- &amp;#223;-D-glucoside; L-mandelo-nitrile-&amp;#223;-D-glucuroniside-6- &amp;#223;-glucoside; L-mandelo-nitrile-beta-glicuronoside and 1-mandelonitrile-beta-glucurooside. To an inexpert eye these names could probably look similar, but they actually represent slightly different compounds and as such they might act differently in the system of our body. &lt;/p&gt;&lt;p&gt;The two clinical trials (non consecutive case series) conducted by Moertel in 1981 (Moertel 1981) and 1982 (Moertel 1982) refer to L-mandelo-nitrile-&amp;#223;-D-glucuroniside-6- &amp;#223;-glucoside and D-mandelonitrile-&amp;#223;-D-glucosido-6- &amp;#223;-D-glucoside respectively, but it is not clear whether the author accidentally wrote the wrong name or was referring to the actual reported name. If so the latter study should not be considered as a follow up of the former one, since the two substances represent a different compound. &lt;/p&gt;&lt;p&gt;A rational nomenclature for phyto-pharmaceuticals is of much importance, because it is the key to any comparison of activity, dosage and even price. In the case of herbal drugs the same extract can have different name or different extract can have the same name, thus creating confusion among the consumer.&lt;br&gt;Processing conditions are the main factors affecting the quality of some Rosaceae seeds ( Hwang 2002, Hu 2002), whereupon companies should ensure correct labelling and accuracy of remedies composition tables in order to facilitate customer's choice.&lt;/p&gt;&lt;p&gt;Laetrile therapies can be offered in different modalities and it is usually not used as a sole therapy, but it may be combined with metabolic therapy, urine therapy, diet therapy, fruit seeds intake (apricot, almond, peach), oral supplements and betaglucuronidase enzyme injections. &lt;/p&gt;&lt;p&gt;The main adverse events observed in cancer patients treated with Laetrile interventions are nausea, vomiting, headache, fever and abdominal pain. Risk to develop adverse effects from cyanide (HCN) poisoning could increase in people with a genetically predisposition diminished capacity to detoxify HCN90 and could also increase with intake of some common foods, such as fresh, sweet almonds (Schmidt 1978). Cyanide poisoning could be also related to an excess and abuse of dosage and especially to the quality of the product. &lt;/p&gt;&lt;p&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ames MM, Moyer TP, Kovach JS, Moertel CG, Rubin J</AU>
<TI>Pharmacology of amygdalin (laetrile) in cancer patients</TI>
<SO>Cancer Chemotherapy Pharmacology</SO>
<YR>1981</YR>
<VL>6(1)</VL>
<PG>51-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cancer-Comm-1953" MODIFIED="2011-09-01 11:00:44 +0100" MODIFIED_BY="Clare Jess" NAME="Cancer Comm 1953" YEAR="1953">
<REFERENCE MODIFIED="2011-09-01 11:00:44 +0100" MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cancer Commission of the California Medical Association</AU>
<TI>Treatment of cancer with laetrile; a report by the Cancer Commission of the California Medical Association</TI>
<SO>California Medicine</SO>
<YR>1953</YR>
<VL>78(4)</VL>
<PG>320-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-CPW_x002d_Rahlstedt-1995" NAME="CPW-Rahlstedt 1995" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>CPW-Rahlstedt Company</AU>
<TI>Summary of clinical efficacy of CDA therapy II</TI>
<SO>Internal data of the company</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guidetti-1955" NAME="Guidetti 1955" YEAR="1955">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guidetti H</AU>
<TI>Preliminary reports on several cases of cancer treated with a cyanogenetic glycoside</TI>
<TO>Observations preliminaries sur quelques cas de cancer traits par un glycuronosyde cyanogenetique</TO>
<SO>Acta</SO>
<YR>1955</YR>
<VL>XI (2)</VL>
<PG>156-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kochi--1980" NAME="Kochi  1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kochi M, Takeuchi S, Mizutani T, Mochizuki K, Matsumoto Y, Saito Y</AU>
<TI>Antitumor activity of benzaldehyde</TI>
<SO>Cancer Treat Reports</SO>
<YR>1980</YR>
<VL>64(1)</VL>
<PG>21-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kochi-1985" NAME="Kochi 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kochi M, Isono N, Niwayama M, Shirakabe K</AU>
<TI>Antitumor activity of a benzaldehyde derivative</TI>
<SO>Cancer Treat Reports</SO>
<YR>1985</YR>
<VL>69(5)</VL>
<PG>533-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moertel-1981" NAME="Moertel 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moertel CG, Ames MM, Kovach JS, Moyer TP, Rubin JR, Tinker JH</AU>
<TI>A pharmacologic and toxicological study of amygdalin</TI>
<SO>The Journal of the American Medical Association</SO>
<YR>1981</YR>
<VL>245(6)</VL>
<PG>591-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moertel-1982" MODIFIED="2011-08-30 14:30:59 +0100" MODIFIED_BY="Heather Maxwell" NAME="Moertel 1982" YEAR="1982">
<REFERENCE MODIFIED="2011-08-30 14:30:59 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moertel CG, Fleming TR, Rubin J, Kvols LK, Sarna G, Koch R, et al</AU>
<TI>A clinical trial of amygdalin (Laetrile) in the treatment of human cancer</TI>
<SO>New England Journal of Medicine</SO>
<YR>1982</YR>
<VL>306(4)</VL>
<PG>201-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morrone-1962" NAME="Morrone 1962" YEAR="1962">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morrone JA</AU>
<TI>Chemotherapy of inoperable cancer: preliminary report of 10 cases treated with laetrile</TI>
<SO>Experimental Medicine Surgery</SO>
<YR>1962</YR>
<VL>20</VL>
<PG>299-308</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Navarro-1957" NAME="Navarro 1957" YEAR="1957">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Navarro MD</AU>
<TI>The mechanism of action and therapeutic effects of laetrile in cancer</TI>
<SO>Journal Philippine Medical Association</SO>
<YR>1957</YR>
<VL>33(8)</VL>
<PG>620-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Navarro-1959" MODIFIED="2011-09-01 10:42:02 +0100" MODIFIED_BY="Clare Jess" NAME="Navarro 1959" YEAR="1959">
<REFERENCE MODIFIED="2011-09-01 10:42:02 +0100" MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Navarro MD</AU>
<TI>Five years experience with laetrile therapy in advanced cancer</TI>
<SO>Acta Unio Internationalis Contra Cancrum</SO>
<YR>1959</YR>
<VL>15</VL>
<PG>209-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Navarro-1964" NAME="Navarro 1964" YEAR="1964">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Navarro MD</AU>
<TI>Laetrile therapy in cancer</TI>
<SO>Acta Unio Internationalis Contra Cancrum</SO>
<YR>1964</YR>
<VL>20</VL>
<PG>392-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sakamoto-1992" NAME="Sakamoto 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sakamoto S, Yoshino H, Shirahata Y, Shimodairo K, Okamoto R</AU>
<TI>Pharmacotherapeutic effects of kuei-chih-fu-ling-wan (keishi-bukuryo-gan) on human uterine myomas</TI>
<SO>Amermican Journal of Chinese Medicine</SO>
<YR>1992</YR>
<VL>20(3-4)</VL>
<PG>313-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Suehiro-2005" MODIFIED="2011-06-23 17:05:25 +0100" MODIFIED_BY="[Empty name]" NAME="Suehiro 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-04-19 10:27:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Suehiro T, Matsumata T, Shikada Y, Sugimachi K</AU>
<TI>The effect of the herbal medicines dai-kenchu-to and keishi-bukuryo-gan on bowel movement after colorectal surgery</TI>
<SO>Hepatogastroenterology</SO>
<YR>2005 Jan-Feb</YR>
<VL>52</VL>
<NO>61</NO>
<PG>97-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tasca-1959" NAME="Tasca 1959" YEAR="1959">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tasca M</AU>
<TI>Clinical observations on the therapeutic effects of a cyanogenetic glycuronoside in cases of human malignant neoplasms</TI>
<SO>Gazzetta Medica Italiana</SO>
<YR>1959</YR>
<VL>118(4)</VL>
<PG>153-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2011-04-19 10:18:20 +0100" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-04-20 10:06:16 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2015-04-20 10:06:16 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Barrett-2011" MODIFIED="2011-06-17 19:43:20 +0100" MODIFIED_BY="[Empty name]" NAME="Barrett 2011" TYPE="OTHER">
<AU>Barrett S</AU>
<TI>Laetrile Spammers Facing $631,585 Penalty</TI>
<SO>www.quackwatch.org/04ConsumerEducation/News/apricotseeds.html (accessed on 3rd May 2011)</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bromley-2005" MODIFIED="2011-08-03 11:06:41 +0100" MODIFIED_BY="Clare Jess" NAME="Bromley 2005" TYPE="JOURNAL_ARTICLE">
<AU>Bromley J, Hughes BG, Leong DC, Buckley NA</AU>
<TI>Life-threatening interaction between complementary medicines: cyanide toxicity following ingestion of amygdalin and vitamin C</TI>
<SO>Annals of Pharmacotherapy</SO>
<YR>2005</YR>
<VL>39</VL>
<NO>9</NO>
<PG>1566-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Calabrese-1979b" NAME="Calabrese 1979b" TYPE="JOURNAL_ARTICLE">
<AU>Calabrese EJ</AU>
<TI>Possible side effects from treatment with laetrile</TI>
<SO>Medical Hypotheses</SO>
<YR>1979</YR>
<VL>5(9)</VL>
<PG>1045-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chan-2006" MODIFIED="2011-08-30 14:31:34 +0100" MODIFIED_BY="Heather Maxwell" NAME="Chan 2006" TYPE="JOURNAL_ARTICLE">
<AU>Chan TY</AU>
<TI>A probable case of amygdalin-induced peripheral neuropathy in a vegetarian with vitamin B12 deficiency</TI>
<SO>Therapeutic Drug monitoring</SO>
<YR>2006</YR>
<VL>28</VL>
<NO>1</NO>
<PG>140-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chang-2006" MODIFIED="2011-09-01 10:42:02 +0100" MODIFIED_BY="Clare Jess" NAME="Chang 2006" TYPE="JOURNAL_ARTICLE">
<AU>Chang HK, Shin MS, Yang HY, Lee JW, Kim YS, Lee MH, et al</AU>
<TI>Amygdalin induces apoptosis through regulation of Bax and Bcl-2 expressions in human DU145 and LNCaP prostate cancer cells</TI>
<SO>Biological &amp; Pharmaceutical Bulletin</SO>
<YR>2006 Aug</YR>
<VL>29</VL>
<NO>8</NO>
<PG>1597-602</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Curran-1980" NAME="Curran 1980" TYPE="JOURNAL_ARTICLE">
<AU>Curran WJ</AU>
<TI>Law-medicine notes. Laetrile for the terminally ill: Supreme Court stops the nonsense</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1980</YR>
<VL>302 (11)</VL>
<PG>619-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davignon-1978" NAME="Davignon 1978" TYPE="JOURNAL_ARTICLE">
<AU>Davignon JP, Trissel LA, Kleinman LM</AU>
<TI>Pharmaceutical assessment of amygdalin (Laetrile) products</TI>
<SO>Cancer Treatment Reports</SO>
<YR>1978</YR>
<VL>62(1)</VL>
<PG>99-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dorr-1978" NAME="Dorr 1978" TYPE="JOURNAL_ARTICLE">
<AU>Dorr RT, Paxinos J</AU>
<TI>The current status of laetrile</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1978</YR>
<VL>89 (3)</VL>
<PG>389-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2011-08-03 11:14:36 +0100" MODIFIED_BY="Clare Jess" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Smith GD, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-2001" NAME="Egger 2001" TYPE="BOOK">
<AU>Egger M</AU>
<SO>Systematic Reviews in Health Care: Meta-Analysis in Context</SO>
<YR>2001</YR>
<EN>2nd</EN>
<PB>BMJ Publishing Group</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ellison-1978" NAME="Ellison 1978" TYPE="JOURNAL_ARTICLE">
<AU>Ellison NM, Byar DP, Newell GR</AU>
<TI>Special report on laetrile: NCI (National Cancer Institute) laetrile review</TI>
<SO>The New England Journal of Medicine</SO>
<YR>September 1978</YR>
<VL>299</VL>
<PG>549-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fenselau-1977" MODIFIED="2011-08-30 14:33:24 +0100" MODIFIED_BY="Heather Maxwell" NAME="Fenselau 1977" TYPE="JOURNAL_ARTICLE">
<AU>Fenselau C, Pallante S, Batzinger RP, Benson WR, Barron RP, Sheinin EB, et al</AU>
<TI>Mandelonitrile beta-glucuronide: synthesis and characterization</TI>
<SO>Science</SO>
<YR>1977</YR>
<VL>198</VL>
<NO>4317</NO>
<PG>625-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fukuda-2003" NAME="Fukuda 2003" TYPE="JOURNAL_ARTICLE">
<AU>Fukuda T, Ito H, Mukainaka T, Tokuda H, Nishino H, Yoshida T</AU>
<TI>Anti-tumor promoting effect of glycosides from Prunus persica seeds</TI>
<SO>Biological and Pharmaceutical Bulletin</SO>
<YR>2003</YR>
<VL>26(2)</VL>
<PG>271-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gibbs-2004" NAME="Gibbs 2004" TYPE="JOURNAL_ARTICLE">
<AU>Gibbs M</AU>
<TI>Networking topics for palliative care</TI>
<SO>The Pharmaceutical Journal</SO>
<YR>2004</YR>
<VL>273</VL>
<NO>7320</NO>
<PG>539</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hu-2002" NAME="Hu 2002" TYPE="JOURNAL_ARTICLE">
<AU>Hu S, Yuan D, Diao GF, Bi KS, Kano Y</AU>
<TI>Studies on evaluation of Semen Armeniacae amarum</TI>
<SO>Zhongguo Zhong Yao Za Zhi (China Journal of Materia Medica)</SO>
<YR>2002</YR>
<VL>27 (10)</VL>
<PG>736-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hwang-2002" MODIFIED="2011-09-01 10:42:02 +0100" MODIFIED_BY="Clare Jess" NAME="Hwang 2002" TYPE="JOURNAL_ARTICLE">
<AU>Hwang EY, Lee JH, Lee YM, Hong SP</AU>
<TI>Reverse-phase HPLC separation of D-amygdalin and neoamygdalin and optimum conditions for inhibition of racemization of amygdalin</TI>
<SO>Chemical and Pharmaceutical Bulletin (Tokyo)</SO>
<YR>2002</YR>
<VL>50</VL>
<NO>10</NO>
<PG>1373-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kwon-2003" NAME="Kwon 2003" TYPE="JOURNAL_ARTICLE">
<AU>Kwon HY, Hong SP, Hahn DH, Kim JH</AU>
<TI>Apoptosis induction of Persicae Semen extract in human promyelocytic leukemia (HL-60) cells</TI>
<SO>Archives of Pharmacal Research</SO>
<YR>2003</YR>
<VL>26</VL>
<NO>2</NO>
<PG>157-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lerner-1981" MODIFIED="2011-08-03 11:07:46 +0100" MODIFIED_BY="Clare Jess" NAME="Lerner 1981" TYPE="JOURNAL_ARTICLE">
<AU>Lerner IJ</AU>
<TI>Laetrile: a lesson in cancer quackery</TI>
<SO>CA: A Cancer Journal for Clinicians</SO>
<YR>1981</YR>
<VL>31</VL>
<NO>2</NO>
<PG>91-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lilienthal-2014" MODIFIED="2015-04-20 10:04:36 +0100" MODIFIED_BY="[Empty name]" NAME="Lilienthal 2014" TYPE="OTHER">
<AU>Lilienthal N</AU>
<TI>Amygdalin - fehlende Wirksamkeit und schdäliche Nebenwirkungen</TI>
<SO>Bulletin zur Arzneimittelsicherheit</SO>
<YR>2014</YR>
<VL>3</VL>
<PG>7-13</PG>
<PB>BfArM - PEI</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Meijer-2001" MODIFIED="2011-06-23 17:06:54 +0100" MODIFIED_BY="[Empty name]" NAME="Meijer 2001" TYPE="OTHER">
<AU>Meijer E</AU>
<TI>Sale over the Internet of substances for human consumption which are regarded as harmful in America</TI>
<SO>Official Journal of the European Communities (2001/C 151 E/071). http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2001:151E:0058:0059:EN:PDF (Last accessed 3rd May 2011)</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Miller-1981" NAME="Miller 1981" TYPE="JOURNAL_ARTICLE">
<AU>Miller KW, Anderson JL, Stoewsand GS</AU>
<TI>Amygdalin metabolism and effect on reproduction of rats fed apricot (Prunus armeniaca) kernels</TI>
<SO>Journal of Toxicology and Environmental Health</SO>
<YR>1981</YR>
<VL>7</VL>
<NO>3-4</NO>
<PG>457-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NCI-2011" MODIFIED="2011-06-17 19:35:52 +0100" MODIFIED_BY="[Empty name]" NAME="NCI 2011" TYPE="OTHER">
<AU>National Cancer Institute</AU>
<TI>Laetrile/Amygdalin (PDQ®)</TI>
<SO>http://www.nci.nih.gov/cancertopics/pdq/cam/laetrile/healthprofessional/allpages (accessed on 16th June 2011)</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Park-HJ-2005" MODIFIED="2011-08-03 11:08:17 +0100" MODIFIED_BY="Clare Jess" NAME="Park HJ 2005" TYPE="JOURNAL_ARTICLE">
<AU>Park HJ, Yoon SH, Han LS, Zheng LT, Jung KH, Uhm YK, et al</AU>
<TI>Amygdalin inhibits genes related to cell cycle in SNU-C4 human colon cancer cells</TI>
<SO>World Journal of Gastroenterology</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>33</NO>
<PG>5156-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parmar-1998" NAME="Parmar 1998" TYPE="JOURNAL_ARTICLE">
<AU>Parmar MK</AU>
<TI>Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints</TI>
<SO>Statistics in Medicine</SO>
<YR>1998</YR>
<VL>17</VL>
<NO>24</NO>
<PG>2815-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Relman-1982" MODIFIED="2011-06-17 19:59:23 +0100" MODIFIED_BY="[Empty name]" NAME="Relman 1982" TYPE="JOURNAL_ARTICLE">
<AU>Relman, A.</AU>
<TI>Closing the books on Laetrile</TI>
<SO>New England Journal of Medicine</SO>
<YR>1982</YR>
<VL>306</VL>
<NO>4</NO>
<PG>236</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schmidt-2004" NAME="Schmidt 2004" TYPE="JOURNAL_ARTICLE">
<AU>Schmidt K, Ernst E</AU>
<TI>Assessing websites on complementary and alternative medicine for cancer</TI>
<SO>Annals of Oncology</SO>
<YR>2004</YR>
<VL>15</VL>
<PG>733-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shaffer-1979" MODIFIED="2011-09-01 10:42:02 +0100" MODIFIED_BY="Clare Jess" NAME="Shaffer 1979" TYPE="OTHER">
<AU>Shaffer David</AU>
<TI>Not available</TI>
<SO>The associated Press</SO>
<YR>July 16, 1979</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shim-2010" MODIFIED="2015-04-16 11:53:21 +0100" MODIFIED_BY="[Empty name]" NAME="Shim 2010" TYPE="JOURNAL_ARTICLE">
<AU>Shim SM, Kwon H</AU>
<TI>Metabolites of amygdalin under simulated human digestive fluids</TI>
<SO>Internationl Journal of Food Sciences and Nutrition</SO>
<YR>2010</YR>
<VL>61</VL>
<NO>8</NO>
<PG>770-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Takafumi-2001" MODIFIED="2011-08-03 11:09:04 +0100" MODIFIED_BY="Clare Jess" NAME="Takafumi 2001" TYPE="JOURNAL_ARTICLE">
<AU>Takafumi I, Yutaka M, Keiichi Y, Noboru K, Tadato T</AU>
<TI>Quantitative determination of amygdalin epimers by cyclodextrin-modified micellar electrokinetic chromatography</TI>
<SO>Journal of Chromatography</SO>
<YR>2001</YR>
<VL>923</VL>
<NO>1-2</NO>
<PG>249-54</PG>
<IDENTIFIERS MODIFIED="2011-03-31 16:25:46 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Therasse-2000" MODIFIED="2011-06-17 20:15:23 +0100" MODIFIED_BY="[Empty name]" NAME="Therasse 2000" TYPE="JOURNAL_ARTICLE">
<AU>Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al</AU>
<TI>New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>2000</YR>
<VL>92</VL>
<NO>3</NO>
<PG>205-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vetter-2000" MODIFIED="2011-06-17 18:09:02 +0100" MODIFIED_BY="[Empty name]" NAME="Vetter 2000" TYPE="JOURNAL_ARTICLE">
<AU>Vetter J</AU>
<TI>Plant cyanogenic glycosides</TI>
<SO>Toxicon</SO>
<YR>2000</YR>
<VL>38</VL>
<NO>1</NO>
<PG>11-36</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2011-08-30 18:35:18 +0100" MODIFIED_BY="Heather Maxwell">
<REFERENCE ID="REF-Milazzo-2006" MODIFIED="2011-08-30 18:35:18 +0100" MODIFIED_BY="Heather Maxwell" NAME="Milazzo 2006" TYPE="COCHRANE_REVIEW">
<AU>Milazzo S, Ernst E, Lejeune S, Boehm K</AU>
<TI>Laetrile treatment for cancer</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2011-08-30 18:35:18 +0100" MODIFIED_BY="Heather Maxwell">
<IDENTIFIER MODIFIED="2011-08-30 18:35:18 +0100" MODIFIED_BY="Heather Maxwell" TYPE="DOI" VALUE="10.1002/14651858.CD005476.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Milazzo-2007" MODIFIED="2011-06-16 21:05:30 +0100" MODIFIED_BY="[Empty name]" NAME="Milazzo 2007" TYPE="JOURNAL_ARTICLE">
<AU>Milazzo S, Lejeune S, Ernst E</AU>
<TI>Laetrile for cancer: a systematic review of the clinical evidence</TI>
<SO>Supportive Care in Cancer</SO>
<YR>2007 June</YR>
<VL>15</VL>
<NO>6</NO>
<PG>583-95</PG>
<IDENTIFIERS MODIFIED="2011-03-31 15:36:47 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2011-09-01 10:31:54 +0100" MODIFIED_BY="Clare Jess">
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2011-09-01 10:31:54 +0100" MODIFIED_BY="Clare Jess" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Ames-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non consecutive case series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cancer-Comm-1953">
<CHAR_REASON_FOR_EXCLUSION>
<P>Consecutive case series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-CPW_x002d_Rahlstedt-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unpublished consecutive case series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Guidetti-1955">
<CHAR_REASON_FOR_EXCLUSION>
<P>Best case series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-04 12:19:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kochi--1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-04 12:19:08 +0100" MODIFIED_BY="[Empty name]">
<P>Benzaldehyde treatment instead of laetrile or amygdalin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-04 12:19:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kochi-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-04 12:19:09 +0100" MODIFIED_BY="[Empty name]">
<P>Benzaldehyde treatment instead of laetrile or amygdalin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Moertel-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non consecutive case series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Moertel-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Consecutive case series study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Morrone-1962">
<CHAR_REASON_FOR_EXCLUSION>
<P>Best case series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Navarro-1957">
<CHAR_REASON_FOR_EXCLUSION>
<P>Best case series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Navarro-1959">
<CHAR_REASON_FOR_EXCLUSION>
<P>Best case series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Navarro-1964">
<CHAR_REASON_FOR_EXCLUSION>
<P>Best case series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-01 10:31:54 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Sakamoto-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-01 10:31:54 +0100" MODIFIED_BY="Clare Jess">
<P>Patients with benign tumor</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-16 21:04:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Suehiro-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-16 20:17:15 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Patients with colorecatal cancer underwent colorectal resection and were administered Dai-ken-chu-to and Keish-bukuryo-gan in order to improve bowel's motility and not as an anticancer treatment. The study says that Keish-bukuryo-gan is prepared with 5 herbs including Prunus persica Batsch. However in the study it is not clear whether it contains Prunus persica seeds. (However in a study from &lt;a link_type=&quot;REFERENCE&quot; href=&quot;Takafumi 2001&quot; protected=&quot;true&quot;&gt;Takafumi 2001&lt;/a&gt;, they developed a method that they used to determine amygdalin epimers &lt;span class=&quot;marker&quot;&gt;&lt;u&gt;&lt;b&gt;in the Chinese herbal prescriptions (Keishi-bukuryo-gan), meaning that it contains amygdalin.&lt;/b&gt;&lt;/u&gt;&lt;/span&gt;&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2011-06-16 20:17:15 +0100" NOTES_MODIFIED_BY="[Empty name]">
<P>Not randomised. Assessed outcome not included (bowel motility)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tasca-1959">
<CHAR_REASON_FOR_EXCLUSION>
<P>Best case series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2011-04-19 10:18:20 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES MODIFIED="2011-09-05 13:34:42 +0100" MODIFIED_BY="Clare Jess"/>
<FEEDBACK>
<FEEDBACK_ITEM ID="FBK-01" NO="1">
<TITLE>Correspondence</TITLE>
<DATE_SUBMITTED>
<DATE DAY="" MONTH="" YEAR=""/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY>
<P>Andrew Vickers, Assistant Attending Research Methodologist<BR/>vickersa@mskcc.org</P>
<P>The authors' state that they: "[have] clearly identified the need for randomised or controlled clinical trials assessing the effectiveness of Laetrile or amygdalin for cancer treatment."</P>
<P>This is to fail completely to understand the nature of oncology research in which agents are tested in randomized trials ("Phase III") only after they have been successful in Phase I and II study. There was a large Phase II study of laetrile (N Engl J Med. 1982 Jan 28;306(4):201-6) which the authors of the review do not cite, they merely exclude as being non-randomized. But the results of the paper are quite clear:<BR/>there was no evidence that laetrile had any effect on cancer (all patients had progression of disease within a few months); moreover, toxicity was reported. To expose patients to a toxic agent that did not show promising results in a single arm study is clinical, scientific and ethical nonsense. </P>
<P>I would like to make a serious recommendation to the Cochrane Cancer group that no reviews on cancer are published unless at least one of the authors either has a clinical practice that focuses on cancer or actively conducts primary research on cancer. My recollection when the Cochrane collaboration was established was that the combination of "methodologic" and "content" expertise was essential.</P>
<P>Submitter agrees with default conflict of interest statement:<BR/>I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of my feedback.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY>
<P>Stefania Milazzo and Ezard Ernst</P>
<P>The view that there is no need for further clinical trials of Laetrile seems entirely reasonable. On the other hand, there are many people out there who promote Laetrile. Firstly they cite non-RCT data which, they claim, is encouraging. Secondly they state that the phase 2 study Vickers refers to was totally flawed. Therefore it might be of benefit to lay this issue at rest by conducting a rigorous RCT. If this prevents cancer patients from being misled into using laetrile, lives could be saved.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS>
<P>Vickers A<BR/>Milazzo S, Ernst E</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2015-04-20 09:59:49 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2015-04-20 09:48:29 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-10-20 10:15:06 +0100" MODIFIED_BY="[Empty name]">Electronic search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2015-04-20 09:48:29 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>CENTRAL</B>
</P>
<P>#1 MeSH descriptor: [Amygdalin] explode all trees<BR/>#2 (amygdalin or amygdaloside or isoamygdalin or neoamygdalin or mandelonitrile or laetrile or laetril or letril or letrile or lactrile)<BR/>#3 MeSH descriptor: [Prunus] explode all trees<BR/>#4 (prunus or prunasin* or prulaurasin or apricot or peach or almond or vitamin B17 or tao ren or tonin or tounin or persica or pesicae or semen armeniacae amarum or keishi-bukuryo-gan or keishibukuryogan or TJ-25 or nitriloside or sarcacinase or C20-H27-N-011 or C14-H15-N-07)<BR/>#5 #1 or #2 or #3 or #4<BR/>#6 MeSH descriptor: [Neoplasms] explode all trees<BR/>#7 (neoplasm* or cancer* or tumor* or tumour* or malignan* or carcinoma* or adenocarcinoma*)<BR/>#8 #6 or #7<BR/>#9 #5 and #8</P>
<P>
<B>MEDLINE Ovid</B>
</P>
<P>1 Amygdalin/<BR/>2 (amygdalin or amygdaloside or isoamygdalin or neoamygdalin or mandelonitrile or laetrile or laetril or letril or letrile or lactrile).mp.<BR/>3 Prunus/<BR/>4 (prunus or prunasin* or prulaurasin or apricot or peach or almond or vitamin B17 or tao ren or tonin or tounin or persica or pesicae or semen armeniacae amarum or keishi-bukuryo-gan or keishibukuryogan or TJ-25 or nitriloside or sarcacinase or C20-H27-N-011 or C14-H15-N-07).mp.<BR/>5 1 or 2 or 3 or 4<BR/>6 exp neoplasms/<BR/>7 (neoplasm* or cancer* or tumor* or tumour* or malignan* or carcinoma* or adenocarcinoma*).mp.<BR/>8 6 or 7<BR/>9 5 and 8<BR/>10 randomized controlled trial.pt.<BR/>11 controlled clinical trial.pt.<BR/>12 randomized.ab.<BR/>13 placebo.ab.<BR/>14 clinical trials as topic.sh.<BR/>15 randomly.ab.<BR/>16 trial.ti.<BR/>17 10 or 11 or 12 or 13 or 14 or 15 or 16<BR/>18 9 and 17</P>
<P>key:<BR/>mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier<BR/>sh=subject heading<BR/>pt=publication type<BR/>ab=abstract</P>
<P>
<B>EMBASE Ovid</B>
</P>
<P>1 amygdalin/<BR/>2 (amygdalin or amygdaloside or isoamygdalin or neoamygdalin or mandelonitrile or laetrile or laetril or letril or letrile or lactrile).mp.<BR/>3 exp Prunus/<BR/>4 (prunus or prunasin* or prulaurasin or apricot or peach or almond or vitamin B17 or tao ren or tonin or tounin or persica or pesicae or semen armeniacae amarum or keishi-bukuryo-gan or keishibukuryogan or TJ-25 or nitriloside or sarcacinase or C20-H27-N-011 or C14-H15-N-07).mp.<BR/>5 1 or 2 or 3 or 4<BR/>6 exp neoplasm/<BR/>7 (neoplasm* or cancer* or tumor* or tumour* or malignan* or carcinoma* or adenocarcinoma*).mp.<BR/>8 6 or 7<BR/>9 5 and 8<BR/>10 crossover procedure/<BR/>11 double-blind procedure/<BR/>12 randomized controlled trial/<BR/>13 single-blind procedure/<BR/>14 random*.mp.<BR/>15 factorial*.mp.<BR/>16 (crossover* or cross over* or cross-over*).mp.<BR/>17 placebo*.mp.<BR/>18 (double* adj blind*).mp.<BR/>19 (singl* adj blind*).mp.<BR/>20 assign*.mp.<BR/>21 allocat*.mp.<BR/>22 volunteer*.mp.<BR/>23 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22<BR/>24 9 and 23</P>
<P>
<B>Search terms for NHS Dialog</B>
<BR/>NHS Dialog is a portal that provides access to databases such as AMED, CINHAL, EMBASE, and MEDLINE. All the above terms were searched in the same way in the NHS Dialog portal, apart from the truncation symbol *, that has been replaced by $. In order to limit truncation and avoid the possibility of overflow, a number of characters after the wildcard was also specified.</P>
<P>
<B>Search terms for CAMbase</B>CAMbase is a virtual search engine with modern XML-based retrieval-technology, which enables the user to easily find relevant literature of Complementary and Alternative Medicine (CAM) in different resources. The use of CAMbase is optimized in such a way that the user can type in a request as a naturally spoken phrase. It is helpful to complete the sentence.<BR/>We used the following sentences:<BR/>
</P>
<UL>
<LI>Laetrile for cancer</LI>
<LI>Vitamin B17 for cancer</LI>
<LI>Amygdalin and cancer</LI>
<LI>Prunus and cancer</LI>
</UL>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>